Introduction

▼
Acetazolamide, N-(5-sulfamoyl-1, 3, 4-thiadiazol-2-yl) acetamide, is an eff ective carbonic anhydrase inhibitor mainly used for the treatment of glaucoma at its early stage. Carbonic anhydrase can reversibly catalyze the hydration of CO 2 and dehydration of carbonic acid. The reaction produces HCO 3 − ion which is responsible for the transportation of Na + ion into the eye.
Then the aqueous humor that can cause the rise of intraocular pressure (IOP) is formed by water and Na + ion inside the eye. And acetazolamide can lower the level of HCO 3 − ion by inhibiting carbonic anhydrase thereby reducing IOP [ 1 ] . Thus, acetazolamide can be eff ectively applied to the treatment of various types of glaucoma. Recently, new applications of acetazolamide have been discovered and studied. For instance, it can be used for the preventive treatment of acute and chronic mountain sickness [ 2 -4 ] . And it may be a potential target for controlling pancreatic cancer by regulating biological behavior of pancreatic cancer cells through inhibition of carbonic anhydrase (CA) I and II [ 5 ] . It can also eff ectively cure refractory epilepsies [ 6 ] and cerebrovascular pathema [ 7 ] , etc. Thus it can be seen that the A simple, rapid and accurate liquid chromatography -tandem mass spectrometry method was developed and validated for the quantifi cation of acetazolamide in beagle plasma using sulfadiazine as the internal standard. After extraction by acetonitrile, the analytes were separated by a rapid gradient elution with acetonitrile and water as the mobile phase on a SHIMADZU VP-ODS C18 column and then detected by an API 4000 triple-quadrupole mass spectrometer using electrospray ionization in negative ion mode.
Multiple reaction monitoring was performed on the ion transitions of m/z 220.9→83.3 (acetazolamide) and m/z 248.9→185.0 (sulfadiazine). The plasma concentration of acetazolamide in beagle dogs showed good linearity over the range of 0.20~50 μg/mL, and the intra-and inter-day variations were small with high accuracy and absolute recovery. Both analytes can maintain stable during the whole experimental process. The developed method was successfully applied to the pharmacokinetic study of acetazolamide extended-release capsules after oral administration to beagle dogs.
plex sample preparation like PH dependent solvent extraction, etc. More recently, LC-mass spectrometry (LC-MS) [ 12 , 13 ] and LC-tandem mass spectrometric (LC-MS/MS) method [ 14 -20 ] have been established. But instead of analyzing plasma concentration of acetazolamide, most of these methods were applied for the determination of acetazolamide in abiotic samples or for screening diuretics in human urine, and the whole analytical period was too long. Even with high selectivity, the sample preparation processes were also very time-consuming and large quantity of biological samples was needed. To sum up, none of these methods can be perfectly suitable for the present high-throughput pharmacokinetic study of acetazolamide in beagle dogs. Therefore, the main goal of this study was to establish and validate a simple, practical and accurate LC-MS/MS method with simplifi ed sample preparation procedures to determine plasma acetazolamide, and further apply it to the pharmacokinetic study of acetazolamide after oral administration of 500 mg AEC to beagle dogs.
Materials and Methods
▼
Chemicals and reagents
The reference substances of acetazolamide (purity > 99.7 %,
• ▶ Fig. 1a ) and the internal standard (IS) sulfadiazine (purity > 99.9 %, • ▶ Fig. 1b ) were obtained from the National Institute for 
Instrumentation and LC-MS/MS conditions
The LC-MS/MS system consisted of a Shimadzu LC-10ADvp series HPLC instrument (Kyoto, Japan) equipped with a PerkinElmer series 200 autosampler (Massachusetts, USA), an API 4 000 triple-quadrupole mass spectrometer equipped with an electrospray ionization source (Applied Biosystems Sciex, Toronto, Canada). Applied Biosystems Analyst software version 1.5.1 package was used to control the LC-MS/MS system for analytical data acquisition and processing. Acetazolamide and IS were separated on a Shimadzu VP-ODS C18 column (150 mm × 2.0 mm, i.d. 5 μm) (Shimadzu, Kyoto, Japan) at a column temperature of 35 °C. The mobile phase containing A (distilled deionized water) and B (acetonitrile) was pumped at a fl ow rate of 0. • ▶ Fig. 2 shows the full-scan negative product ion mass spectra of aceta- zolamide and IS. The optimized working parameters for mass spectrometer were as follows: dwell time, 200 ms; ion spray voltage, − 4.5 kV; gas temperature, 400 °C; collision-activated dissociation (CAD) 4 psi; declustering potential (DP), − 50 V; nebulizer gas (N 2 ), 20 psi; curtain gas (N 2 ), 10 psi; auxiliary gas (N 2 ), 20 psi; collision energy, − 28 V (acetazolamide) and − 27 V (IS).
Preparation of stock and working solutions
The stock solutions of acetazolamide and IS were separately prepared in methanol at the concentration of 1 mg mL − 1 and stored in brown volumetric fl asks at 4 °C before use. A series of working solutions of acetazolamide (0.4, 1, 2, 4, 10, 20, 40, 100 μg/mL) and IS standard solution (2 μg/mL) were prepared by diluting stock solutions of the analyte and IS with the mobile phase.
Calibration standards and quality control samples
The calibration standards of acetazolamide were prepared by spiking acetazolamide working solutions into equal volume of blank beagle plasma to obtain the series concentrations of 0.2, 0.5, 1, 2, 5, 10, 20, 50 μg/mL. Quality control (QC) samples were prepared in the same way as calibration standards to achieve the fi nal concentrations of 0.5, 5 and 40 μg/mL. All samples were stored at 4 °C until analysis.
Plasma sample preparation
For the preparation of plasma samples, a 100 μL of aliquot plasma sample was mixed with 100 μL of IS standard solution (2 μg/mL). The plasma mixture was precipitated by 600 μL of acetonitrile, vortex-mixed for 1 min and then centrifuged at 16 000 × g for 10 min. Finally, 5 μL of the supernatant was directly injected onto the LC-MS/MS system for analysis.
Application to a pharmacokinetic study 6 healthy beagle dogs (3 males and 3 females, 9.6 ± 0.23 Kg) were purchased from Shanghai Xin'gang laboratory animal center (Shanghai, China). The whole process of the animal experiment was carried out according to the guidance of the Animal Ethics Committee in China Pharmaceutical University. All dogs were kept in separate cages and given natural light with ad libitum access to standard laboratory diet and clean water. Prior to administration, the dogs were fasted overnight and fed at 8 h post-dose. They were randomly divided into 2 experimental groups. 2-period crossover design was carried out for the experiment with a wash-out period of 1 week long. After an oral administration of 1 test capsule or one reference capsule (containing 500 mg acetazolamide) to each dog with 30 mL water, approximately 2.5 mL of blood samples were collected from the forelimb vein into heparinized tubes at the following time points: 0 h (before dosing) and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 30, 36 h after dosing. Plasma samples were then separated by centrifugation at 4 000 × g for 5 min and kept at − 75 °C until analysis.
Data analysis
The pharmacokinetic parameters were processed by non-compartmental analysis using DAS (Drug and statistics) 2.1.1 software (Mathematical Pharmacology Professional Committee of China).
Results
▼
Method validation
A full method validation was performed according to the US FDA guidelines [ 21 ] .
Specifi city and selectivity
The specifi city was assessed by analyzing 6 diff erent batches of blank beagle plasma.
• ▶ Fig. 3 shows the typical MRM chromatograms of blank beagle plasma ( • ▶ Fig. 3a ), spiked plasma with acetazolamide at the lower limit of quantifi cation (LLOQ) and IS ( • ▶ Fig. 3b ), and plasma sample obtained from beagle dogs at 1 h after oral administration ( • ▶ Fig. 3c ). The results suggested that there was no signifi cant interference on the determination of acetazolamide and IS from beagle plasma, and this method showed good specifi city and selectivity for the following pharmacokinetic study. Under the conditions of this experiment, the retention times of acetazolamide and IS were 2.86 min and 2.92 min, respectively.
Linearity and sensitivity
The calibration curves were prepared at the concentration levels of 0.2, 0.5, 1, 2, 5, 10, 20, 50 μg/mL for acetazolamide in beagle plasma and were constructed by plotting peak area ratios of 
Precision and accuracy
5 replicates of the 3 QC concentration levels (0.5, 5, 40 μg/mL) were analyzed to evaluate the intra-day precision and accuracy, the QC samples were prepared according to the method in "Sample preparation". The same procedure was performed once a day in 3 consecutive days to determine the inter-day precision. Accuracy was the ratio of measured concentration to theoretical concentration. The relative standard deviation (RSD) and the relative error (RE) of the concentration data obtained should be within ± 20 % for low QC concentrations and within ± 15 % for middle and high QC concentrations.
The results of precision (intra-and inter day precision) and accuracy data were summarized in • ▶ Table 1 . The RSD values of intra-and inter-day precision were all less than 5 %, and accuracy results can meet the demands of determination.
Matrix eff ect and absolute recovery
To investigate the matrix eff ect, peak area of post-preparative blank plasma sample spiked with acetazolamide at 3 QC concentration levels were compared to that of standard solutions which were directly diluted by mobile phase to the same concentrations. The peak area ratios were used to evaluate matrix eff ect. The matrix eff ect results for acetazolamide were 101.3 ± 4.2 %, 103.1 ± 4.1 % and 100.4 ± 6.2 % at low, middle and high QC concentrations, respectively and no less than 95 % for IS, suggesting that there were no interferences from plasma matrix on the detection of both analytes. Absolute recovery of acetazolamide was measured by comparing the peak area of 3-level QC plasma samples to that of the 3-level QC standard solutions which were directly diluted by mobile phase. The results in • ▶ Table 2 showed that the absolute recovery of the method was high enough for the analysis of acetazolamide in beagle plasma.
Stability
The stability of acetazolamide in plasma under various conditions was evaluated. Three-level QC samples were stored at room temperature for 4 h before preparation and kept at 4 °C for 24 h after preparation. The QC samples also underwent three freeze ( − 75 °C) -thaw cycles and long-term freezing ( − 75 °C) condition for 30
days. The results of • ▶ Table 3 showed that plasma samples were stable under all storage conditions described.
Pharmacokinetic study
In pharmacokinetic study, 6 healthy beagles were randomly divided into 2 groups, and a randomized, 2-way cross-over experiment was carried out to determine the relative bioavailability of AEC (containing 500 mg of acetazolamide per capsule). 
Discussion
▼
Optimization of MS/MS parameters and chromatographic separation conditions
To avoid the interference from plasma and further improve selectivity, tandem mass spectrometry is a more preferable method. In the present study, MS/MS detection was performed and electrospray ionization (ESI) source was adopted. In order to obtain the best MS/MS conditions for the detection of the analytes, standard solutions (1.0 μg/mL) of acetazolamide and IS were directly injected into mass spectrometer by a syringe pump and scanned under positive and negative MRM mode, respectively. And the negative mode showed higher ion intensities for both analytes. Under the full-scan mode in Q1 mass, the ion spray voltage, nebulizer gas, auxiliary gas, curtain gas and declustering potential were all tuned according to the ion signal response to achieve the highest selectivity and stability. Finally, the deprotonated molecule
, m/z 220.9 for acetazolamide and m/z 248.9 for IS were selected as the parent ions. Then the product ion scan was performed, the parent ions were introduced to the Q2 mass spectrometer, and the MS/MS fragmentations resulted in product ions m/z 83.3 for acetazolamide and m/z 185.0 for IS with the optimum collision energy set of − 28 V and − 27 V, respectively. After collision-activated dissociation (CAD) using nitrogen as collision gas and further optimization of the MS/MS parameters in MRM mode, the ion transitions of m/z 220.9→83.3 and m/z 248.9→185.0 with the highest selectivity and ion response ( > 2.0 × 10 6 ) were chosen for the detection of acetazolamide and IS, respectively. During the process of optimizing the chromatographic conditions, in order to achieve high resolution, shorter run time and better peak shapes, various compositions and proportions of mobile phase have been investigated. At the very start, isocratic elution by methanol and water was tried, while the peak shapes were not symmetrical, sharp or smooth, and the retention times of both analytes were relatively long. Then, gradient elution was adopted, and the peak shapes were better improved, but the smoothness was still not so satisfying. Considering this situation, the organic phase was replaced by acetonitrile because its elutive power was higher than methanol, and then the analytes could be more suffi ciently separated from water-soluble impurities and eluted within proper time, thus obtaining smooth and sharp peak shapes without interference and higher ion response as well as shortening the whole analysis period. The retention behaviors of analytes on diff erent chromatographic columns have also been investigated. After comparison, Shimadzu VP-ODS C18 chromatographic column was found to be the best choice for the separation of analytes because of its low matrix eff ects and high column effi ciency. At the injection volume of 10 μL, the peak shapes of analytes turned out to be asymmetric, this phenomenon was likely caused by sample overload. After reducing the sample injection volume to 5 μL, the peak shapes of analytes resulted to be more symmetric and beautiful. Finally, a gradient elution on Shimadzu VP-ODS C18 chromatographic column with acetonitrile and water as the mobile phase at a fl ow rate of 0.35 mL/min was proved to be the most appropriate condition that could achieve the highest separation effi ciency. Compared with other publications [ 14 -20 ] involving LC-MS/MS method, the determination of acetazolamide under the optimized LC-MS/MS conditions in this study could achieve better resolution and higher ion response, shorter retention times and especially perfect peak shapes. The high MS/MS ion intensity and eff ective chromatographic separation could not only facilitate the whole analytical process, but also provide more accurate results with minimum interference of endogenous materials form plasma on the separation and detection of the analytes. 
Selection of IS
Sulfadiazine was selected as the internal standard in this method mainly because of its high ionization effi ciency under ESI source and similar chromatographic separation properties with acetazolamide, so that the optimization process could be unifi ed and effi cient. Moreover, sulfadiazine can maintain its stability during sample preparation and the whole determination process.
Sample pretreatment
In pharmacokinetic studies, sample pretreatment method is crucial since errors caused by operation and low recovery usually can be introduced in this section. The most common sample preparation method for plasma acetazolamide was liquid-liquid extraction (LLE) in the earlier publications [ 9 , 10 ] of which the developed sample pretreatment methods were not only complex, but also time-consuming. While in this study, sample pretreatment could be simplifi ed due to the improved sensitivity and selectivity of our current established LC-MS/MS conditions under which the protein precipitation method could also meet the requirement for acetazolamide determination and obtain higher absolute recovery. As a result, protein precipitation adopted in the current study was not only rapid and convenient but also had good reproducibility, thus simplifying and speeding up the entire pharmacokinetic study.
Method application
As obviously can be seen in • ▶ Fig. 5 , the plasma concentrationtime profi les of acetazolamide in test and reference formulation were almost consistent and there was also no signifi cant statistical diff erence between each primary pharmacokinetic parameter of the two formulations. Thus, we can conclude that with similar pharmacokinetic behaviors, test formulation was proved to have the same sustained releasing eff ects with reference formulation and two formulations were bioequivalent in beagle dogs after oral administration.
Conclusions
▼
A simple, practical and accurate LC-MS/MS method for the determination of plasma acetazolamide has been established and validated. And the pharmacokinetic behavior of acetazolamide after oral administration of AEC to beagle dogs has been successfully analyzed by using the developed method. As discussed above, the sample pretreatment process has been greatly simplifi ed owing to the optimized LC-MS/MS conditions in current study, thus saving time and money. In summary, this method showed its highly convenience and reliability for the rapid determination of acetazolamide in high-throughput pharmacokinetic studies.
